Study The Role of Serotonin 2B Receptor in Osteoclastogenesis

Abstract

Osteoporosis is one of the most disease in menopausal women, middle‐aged and elderly people and it's second only to cardiovascular disease. Overexpression of osteoclastogenesis in the body resulting in outflow of sclerotic is one the main reason to cause osteoporosis. In recent years, clinical research has found persisting in taking anti‐depression drugs',Selective Serotonin Reuptake Inhibitor, SSRI, patients have higher ratio to suffer osteoporosis. It means serotonin, 5‐HT, should involve in the regulation of sclerotic metabolism. The researches demonstrated that there are many types of 5‐HT receptor, 5‐HTR, expressing in the human cell and regulate different physiological functions. In previous reports indicated both osteoblasts and osteoclasts expressing 5‐HT2BR. 5‐HT2BR can promote osteoblast proliferation and differentiation, but the effect on osteoclasts is unknown. In this study, we utilized receptor activator of nuclear factor kappa‐B ligand, RANKL to induce RAW264.7 cell differentiating to osteoclast as a model, and investigated how does the concentration of 5‐HT and 5‐HT2BR antagonist affect osteoclast differentiation. The result suggested that the degree of osteoclast differentiation was positive correlation with concentration of 5‐HT, and 5‐HT2BR antagonist treatment could reduce osteoclasts formation. In short, this investigation confirmed 5‐HT2BR involved in regulating osteoporosis. In the future, the further exploration will aim to intracellular signaling pathways. This research might provide another direction of prophylaxis and therapy for osteoporosis.